Biospecimen Collection (NCT03739814)

Name: Biospecimen Collection trial for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (NCT03739814)
Uploaded: 2026-10-31T05:31:43.233Z
Duration: 1 min 21 s
Description: Biospecimen Collection trial for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (NCT03739814). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT03739814.

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia: a one-minute explainerNCT037398141 min

Biospecimen Collection trial for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (NCT03739814). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with CD22-positive B-cell acute lymphoblastic leukemia. Philadelphia-negative groups require newly diagnosed disease at 60+, without planned transplant, or relapsed/refractory disease in first/second salvage. Philadelphia-positive patients require newly diagnosed disease and either age 75+ or HyperCVAD ineligibility.

The idea: sequence inotuzumab ozogamicin, delivering a CD22-targeted toxin, and blinatumomab, linking immune cells to leukemia. The Philadelphia-positive group adds ponatinib; response determines later treatment. Marrow biopsies and spinal taps monitor disease.

This phase 2 study plans 84 patients. NCI sponsors it; 87 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.